This included two drugs that inhibit tumor angiogenesis and proliferation, two drugs that target and inhibit the cellular proteasome, two mTOR inhibitors targeting the PI3K/Akt/mTOR pathway, 11 tyrosine kinase inhibitors targeting the PI3K/AKT and MAPK pathways, nine drugs targeting the ATM gene to block DNA synthesis, inhibit nucleotide metabolism, and induce cell apoptosis, and 3 MEK signaling pathway inhibitors [30]. The gene discussed is MAP2K7; the disease is neoplasm.